<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00406575</url>
  </required_header>
  <id_info>
    <org_study_id>RLX.CHF.002</org_study_id>
    <nct_id>NCT00406575</nct_id>
  </id_info>
  <brief_title>Recombinant Human Relaxin for the Treatment of Decompensated CHF</brief_title>
  <official_title>A Phase II Randomized, Double Blind, Placebo-Controlled Study of Recombinant Human Relaxin in Patients With Decompensated Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies</source>
  <brief_summary>
    <textblock>
      Two doses of relaxin will be compared to placebo for the treatment of patients with
      decompensated CHF
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pilot clinical data suggest that recombinant human relaxin may be effective in treating
      patients with decompensated CHF. This study will randomize patients in blinded manner to one
      of two doses of intravenous relaxin or placebo. Serial evaluations will include cardiac and
      renal function, as well as safety and tolerability.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac hemodynamics</measure>
    <time_frame>Baseline through 27 hours post-infusion or discharge from the hospital.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Baseline through Day 10</time_frame>
    <description>Renal function was to be assessed by evaluation of serum creatinine, creatinine clearance, BUN, uric acid, GFR, RBF, urine output, sodium clearance, and body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability assessed by number of patients with adverse events (AEs)</measure>
    <time_frame>Baseline through Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Congestive Heart Failure (CHF)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive diluent via continuous IV infusion for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose rhRlx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 100 µg/kg/day (corresponding to a dose of 4.2 µg/kg/hr).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose rhRlx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 500 µg/kg/day (corresponding to a dose of 21.0 µg/kg/hr).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo was the diluent used for preparation of the 100 µg/kg/day dose of active study medication.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Diluent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human relaxin (rhRlx)</intervention_name>
    <description>Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.</description>
    <arm_group_label>Low Dose rhRlx</arm_group_label>
    <arm_group_label>High Dose rhRlx</arm_group_label>
    <other_name>serelaxin</other_name>
    <other_name>serelaxin (RLX030)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalization

          -  Decompensated chronic CHF (NYHA Class III-IV)

          -  LVEF &lt; 35%

          -  PCWP &gt; 22 mmHg

          -  CI &lt; 2.3 L/min/m2

        Exclusion Criteria:

          -  Acute CHF

          -  Acute coronary syndrome

          -  Hypotension or shock

          -  Recent stroke

          -  Allergy or sensitivity to test agents

          -  Significant confounding conditions or medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Dschietzig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite Hospital, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Russian Scientific Centre of Surgery n.a. B.V.Petrovsky of Russian Academy of Medical Sciences</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Educational Scientific Medical Center of the General Management Department of the President of Russian Federation. City Clinical Hospital №51</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2006</study_first_submitted>
  <study_first_submitted_qc>November 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <last_update_submitted>May 6, 2014</last_update_submitted>
  <last_update_submitted_qc>May 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Congestive heart failure</keyword>
  <keyword>Relaxin</keyword>
  <keyword>Hemodynamics</keyword>
  <keyword>Renal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methocarbamol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

